In the search for new pharmacological targets to treat IBDs, in the same vein as AnxA1, peroxisome proliferator activated γ (PPARγ) has been explored as a potential transcription factor linked to modulation of IBD, and it has been evidenced its impaired expression is linked to disease progression in humans (Yamamoto-Furusho et al., 2011; Dou et al., 2015). Here, PPARG is linked to inflammatory bowel disease.